Kesheng Dai

Prof. Dr. Kesheng Dai


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MCMengxing Chen
Mengxing Chen
RYRong Yan
Rong Yan
KZKangxi Zhou
Kangxi Zhou
XLXiaodong Li
Xiaodong Li
YZYang Zhang
Yang Zhang
KDKesheng Dai
Kesheng Dai
Significance: Immune thrombocytopenia (ITP) patients with antiplatelet glycoprotein (GP) Ib-IX autoantibodies appear refractory to conventional treatments; however, the mechanism remains elusive. Here we show that the platelets undergo apoptosis in ITP patients with anti-GPIbα autoantibodies. We demonstrate that anti-GPIbα antibody binding activates Akt, which elicits platelet apoptosis through activation of phosphodiesterase (PDE3A) and PDE3A-mediated PKA inhibition. Phosphatidylserine (PS) exposure results in phagocytosis of anti-GPIbα antibody-bound platelets by macrophages in the liver. Notably, inhibition or genetic ablation of Akt or Akt-regulated apoptotic signaling or blockage of PS exposure rescues the platelets from clearance. Therefore, our findings reveal pathogenic mechanisms of ITP with anti-GPIbα autoantibodies and, more importantly, suggest therapeutic strategies for thrombocytopenia caused by autoantibodies or other pathogenic factors.

23 October 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ZLZhao Lili
Zhao Lili
JLJUN LIU
JUN LIU
CHChunyan He
Chunyan He
RYRong Yan
Rong Yan
KZkangxi zhou
kangxi zhou
KDKesheng Dai
Kesheng Dai
Apoptosis delimits platelet life span in the circulation and leads to storage lesion, which severely limits the shelf life of stored platelets. Moreover, accumulating evidence indicates that platelet apoptosis provoked by various pathological stimuli results in thrombocytopenia in many common diseases. However, little is known about how platelet apoptosis is initiated or regulated. Here, we show that PKA activity is markedly reduced in platelets aged in vitro, stored platelets, and platelets from patients with immune thrombocytopenia (ITP), diabetes, and bacterial infections. Inhibition or genetic ablation of PKA provoked intrinsic programmed platelet apoptosis in vitro and rapid platelet clearance in vivo. PKA inhibition resulted in dephosphorylation of the proapoptotic protein BAD at Ser155, resulting in sequestration of prosurvival protein BCL-XL in mitochondria and subsequent apoptosis. Notably, PKA activation protected platelets from apoptosis induced by storage or pathological stimuli and elevated peripheral platelet levels in normal mice and in a murine model of ITP. Therefore, these findings identify PKA as a homeostatic regulator of platelet apoptosis that determines platelet life span and survival. Furthermore, these results suggest that regulation of PKA activity represents a promising strategy for extending platelet shelf life and has profound implications for the treatment of platelet number-related diseases and disorders.

27 February 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
YZYiwen Zhang
Yiwen Zhang
JZJian Zhang
Jian Zhang
RYRong Yan
Rong Yan
JTJingluan Tian
Jingluan Tian
YZYang Zhang
Yang Zhang
KDKesheng Dai
Kesheng Dai
Significance: Receptor-interacting protein kinase 3 (RIP3) is involved in many important biological processes such as necroptosis, apoptosis, and inflammation. Here, using RIP3 -knockout mice, we show that RIP3 is essential for in vivo thrombosis and hemostasis. Mice lacking RIP3 exhibited prolonged tail-bleeding times and reduced arterial thrombus formation. We demonstrate that RIP3, expressed in platelets and interacting with Gα 13 , promotes platelet aggregation, secretion, spreading on fibrinogen, and clot retraction. RIP3 inhibitor dose-dependently inhibits platelet aggregation and prevents arterial thrombus formation. Our findings indicate a role for RIP3 in promoting in vivo thrombosis and hemostasis by amplifying platelet activation. RIP3 may represent a novel therapeutic target for thrombotic diseases.

1 January 2015 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
NMNa Ma
Na Ma
LZLili Zhao
Lili Zhao
CLCao Lijuan
Cao Lijuan
YZYiwen Zhang
Yiwen Zhang
JZJie Zhang
Jie Zhang
KDKesheng Dai
Kesheng Dai
Summary: Many immune thrombocytopenia (ITP) patients, particularly patients with anti-glycoprotein (GP) Ib-IX autoantibodies, do not respond to the conventional treatments such as splenectomy. However, the underlying mechanism remains unclear. Here we found that anti-GPIbα N-terminus antibody AN51, but not other anti-GPIbα antibodies (AK2, HIP1, VM16d, or WM23), induced GPIbα clustering that led to integrin αIIbβ3-dependent platelet aggregation. After intravenous injection, AN51 dose-dependently induced thrombocytopenia in guinea pigs, and the platelets were mainly removed by macrophages in the liver. N-acetyl-D-glucosamine, previously shown to inhibit integrin αMβ2-mediated phagocytosis of refrigerated platelets, dose-dependently inhibited AN51-induced platelet clearance. Furthermore, AN51 but not VM16d, induced rapid platelet clearance in the liver of cynomolgus macaques. Five of 22 chronic ITP patients had anti-GPIbα autoantibodies, and the autoantibodies from four of the five patients competed with AN51 for binding to platelets. These data indicate that GPIbα clustering induced by anti-GPIbα N-terminus antibody causes integrin αIIbβ3-dependent platelet aggregation, phagocytosis, and rapid platelet clearance in the liver. Our findings reveal a novel Fc-independent mechanism underlying the pathogenesis of ITP, and suggest new therapeutic strategies for ITP patients with anti-GPIbα autoantibodies.

12 January 2017 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
LLLei Liu
Lei Liu
MCMengxing Chen
Mengxing Chen
LZLili Zhao
Lili Zhao
QZQing Zhao
Qing Zhao
RHRenping Hu
Renping Hu
KDKesheng Dai
Kesheng Dai

30 December 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
LHLulu Han
Lulu Han
YMYutong Miao
Yutong Miao
YZYang Zhao
Yang Zhao
XZXingzhong Zhang
Xingzhong Zhang
XMXiaolong Ma
Xiaolong Ma
XWXian Wang
Xian Wang
Hyperhomocysteinemia (HHcy) is associated with an exaggerated platelet thrombotic response at sites of vascular injury. In this study, human medical examination showed that elevated human plasma Hcy levels correlated positively with enhanced blood coagulation and platelet activity, suggesting that humans with HHcy are more prone to thrombus formation at the sites of vascular injury. Accordingly, we observed accelerated platelet activation, primary hemostasis, and thrombus formation in apolipoprotein E-deficient (ApoE−/−) mice with acute or chronic HHcy. Upon homocysteine (Hcy) administration in C57BL/6J mice, platelet aggregation, spreading and clot retraction were markedly induced. More important, Hcy increased the affinity of platelet integrin αIIbβ3 with ligands and enhanced integrin outside-in signaling by promoting membrane phosphatidylserine exposure in vitro. Mechanistically, lipidomics analysis showed that lysophosphatidylcholines were the primary metabolites leading to clustering of HHcy-stimulated platelets. Cytosolic phospholipase A2 (cPLA2) activity and autotaxin (ATX, a secreted lysophospholipase D) secretion were upregulated by Hcy, leading to membrane phospholipid hydrolysis and PS exposure. Moreover, secreted ATX directly interacted with integrin β3. Inhibitors of cPLA2 and ATX activity blocked integrin αIIbβ3 outside-in signaling and thrombosis in HHcy ApoE−/− mice. In this study, we identified a novel mechanism by which HHcy promotes platelet membrane phospholipid catabolism and extracellular ATX secretion to activate integrin outside-in signaling, consequently exacerbating thrombosis and the results revealed an innovative approach to treating HHcy-related thrombotic diseases.